ANGLE Valuation

Is AGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGL?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AGL. This is calculated by dividing AGL's market cap by their current preferred multiple.
What is AGL's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	UK£25.80m

AGL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6x
Enterprise Value/EBITDA	-0.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AGL's PS Ratio compare to its peers?

The above table shows the PS ratio for AGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.3x
BELL Belluscura	12.7x	151.8%	UK£17.7m
OBI Ondine Biomedical	26x	66.1%	UK£23.6m
EMVC EMV Capital	5.9x	24.9%	UK£10.7m
POLX Polarean Imaging	12.8x	57.3%	UK£18.4m
AGL ANGLE	12.7x	51.4%	UK£25.8m

Price-To-Sales vs Peers: AGL is good value based on its Price-To-Sales Ratio (12.7x) compared to the peer average (14.3x).

Price to Earnings Ratio vs Industry

How does AGL's PE Ratio compare vs other companies in the GB Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: AGL is expensive based on its Price-To-Sales Ratio (12.7x) compared to the UK Medical Equipment industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is AGL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.7x
Fair PS Ratio	0.6x

Price-To-Sales vs Fair Ratio: AGL is expensive based on its Price-To-Sales Ratio (12.7x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGL forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	UK£0.08	UK£0.69 +756.3%	2.2%	UK£0.70	UK£0.67	n/a	2
Oct ’25	UK£0.083	UK£0.69 +730.3%	2.2%	UK£0.70	UK£0.67	n/a	2
Sep ’25	UK£0.13	UK£0.69 +417.0%	2.2%	UK£0.70	UK£0.67	n/a	2
Aug ’25	UK£0.14	UK£0.69 +380.7%	2.2%	UK£0.70	UK£0.67	n/a	2
Jul ’25	UK£0.14	UK£0.69 +372.4%	2.2%	UK£0.70	UK£0.67	n/a	2
Jun ’25	UK£0.19	UK£0.69 +265.3%	2.2%	UK£0.70	UK£0.67	n/a	2
May ’25	UK£0.14	UK£0.69 +389.3%	2.2%	UK£0.70	UK£0.67	n/a	2
Apr ’25	UK£0.13	UK£0.69 +448.0%	2.2%	UK£0.70	UK£0.67	n/a	2
Mar ’25	UK£0.16	UK£0.69 +328.1%	2.2%	UK£0.70	UK£0.67	n/a	2
Feb ’25	UK£0.17	UK£0.69 +302.9%	2.2%	UK£0.70	UK£0.67	n/a	2
Jan ’25	UK£0.12	UK£0.97 +728.4%	18.9%	UK£1.20	UK£0.75	n/a	3
Dec ’24	UK£0.12	UK£0.97 +704.4%	18.9%	UK£1.20	UK£0.75	n/a	3
Nov ’24	UK£0.12	UK£0.97 +728.4%	18.9%	UK£1.20	UK£0.75	UK£0.077	3
Oct ’24	UK£0.15	UK£0.97 +538.2%	18.9%	UK£1.20	UK£0.75	UK£0.083	3
Sep ’24	UK£0.12	UK£0.94 +700.0%	24.0%	UK£1.20	UK£0.65	UK£0.13	3
Aug ’24	UK£0.14	UK£0.94 +548.3%	24.0%	UK£1.20	UK£0.65	UK£0.14	3
Jul ’24	UK£0.13	UK£0.94 +637.3%	24.0%	UK£1.20	UK£0.65	UK£0.14	3
Jun ’24	UK£0.18	UK£0.94 +415.1%	24.0%	UK£1.20	UK£0.65	UK£0.19	3
May ’24	UK£0.23	UK£0.94 +313.2%	24.0%	UK£1.20	UK£0.65	UK£0.14	3
Apr ’24	UK£0.20	UK£1.45 +625.0%	17.2%	UK£1.70	UK£1.20	UK£0.13	2
Mar ’24	UK£0.25	UK£1.45 +485.9%	17.2%	UK£1.70	UK£1.20	UK£0.16	2
Feb ’24	UK£0.29	UK£1.45 +400.0%	17.2%	UK£1.70	UK£1.20	UK£0.17	2
Jan ’24	UK£0.51	UK£2.06 +306.9%	17.3%	UK£2.41	UK£1.70	UK£0.12	2
Dec ’23	UK£0.54	UK£2.06 +284.1%	17.3%	UK£2.41	UK£1.70	UK£0.12	2
Nov ’23	UK£0.60	UK£2.06 +242.5%	17.3%	UK£2.41	UK£1.70	UK£0.12	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.